Proteins adopt different higher-order structures (HOS) to enable their unique biological
functions. Understanding the complexities of protein higher-order structures and dynamics …

Protein biopharmaceuticals are macromolecules with a therapeutic effect, commonly
produced by the recombinant DNA technology. They have emerged as important …

Adaptive changes in lysosomal capacity are driven by the transcription factors TFEB and
TFE3 in response to increased autophagic flux and endolysosomal stress, yet the molecular …

Covalent labeling of proteins in combination with mass spectrometry has been established
as a complementary technique to classical structural methods, such as X-ray, NMR, or …

Nanoparticle-based drug delivery systems, in combination with high-affinity disease-specific
targeting ligands, provide a sophisticated landscape in cancer theranostics. Due to their …

The extensive analytical characterization of protein biotherapeutics, especially of
biosimilars, is a critical part of the product development and registration. High-resolution …

Hydroxyl radical footprinting (HRF) of proteins with mass spectrometry (MS) is a widespread
approach for assessing protein structure. Hydroxyl radicals react with a wide variety of …

Amyloid aggregates are associated with several debilitating diseases, and there are
numerous efforts to develop small molecule treatments against these diseases. One …

Protein footprinting mediated by mass spectrometry has evolved over the last 30 years from
proof of concept to commonplace biophysics tool, with unique capabilities for assessing …

Higher-order structure (HOS) is a crucial determinant for the biological functions and quality
attributes of protein therapeutics. Mass spectrometry (MS)-based protein footprinting …